GENE ONLINE|News &
Opinion
Blog

2021-10-20| Asia-Pacific

South Korea’s D&D Pharmatech Secures $51M Series C, Eyes 2022 IPO

by Kathy Huang
Share To

South Korea’s D&D Pharmatech has completed a $51 million Series C funding. The company also announced its plan for an IPO in South Korea in 2022, while pre-IPO round funding will be used to advance clinical trials for diabetes, nonalcoholic fatty liver disease, and neurodegenerative diseases.  

The latest round was led by Praxis Capital Partners, with participation from other investors including DS Asset Management, Kudos Ventures and Korea Investment & Securities. In an earlier Series B in August 2019, D&D raised $137.1 million. 

 

Use of the Proceeds 

The cash will be used to support D&D’s clinical trials in three ways. First, it will push DD01, a treatment for diabetes and nonalcoholic fatty liver disease, into Phase 2. DD01 is a dual agonist of GLP-1R and glucagon receptor (GCGR). Animal studies show that DD01 causes weight loss, reduced liver fat, and better glucose tolerance in mice.

Secondly, the company will continue the Phase 2 studies of NLY01 for Parkinson’s and Alzheimer’s disease. NLY01 is a long-acting, microglia-targeted glucagon-like peptide-1 receptor (GLP-1R) agonist. The drug candidate can penetrate the blood-brain barrier and prolong the neuron cell lifespan, improving the cognition of Parkinson’s and Alzheimer’s patients. 

Thirdly, D&D will proceed with preclinical studies of TLY02. TLY02 targets myofibroblasts, the originator of fibrotic diseases. Fibrosis causes various disorders ranging from systemic sclerosis, chronic pancreatitis to cancers.      

“We look forward to the ongoing advancement of our clinical candidates in a diverse range of diseases with significant unmet need and the expansion of our pipeline with potentially game-changing therapeutics, ” said Yoo-Seok Hong, CEO of D&D.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Biogen Concludes $900 Million Settlement Before Posting Positive Data From Alzheimer’s Trial
2022-09-28
Arsenal Biosciences Announced Another $70 million Collaboration, This Time With Genentech
2022-09-27
Forge Biologics Raises $90 Million To Expand Gene Therapy CDMO
2022-09-14
LATEST
AstraZeneca Welcomes Neurofibromatosis And Asthma Treatment Approvals in Japan
2022-09-28
Biogen Concludes $900 Million Settlement Before Posting Positive Data From Alzheimer’s Trial
2022-09-28
Arsenal Biosciences Announced Another $70 million Collaboration, This Time With Genentech
2022-09-27
Sciwind Biosciences And SynerK Join Forces To Develop siRNA Therapeutics
2022-09-27
Acticor Enrolls First Patient in Phase 2/3 Stroke Treatment Study
2022-09-27
Daiichi Sankyo Wins Approval For Cancer Treatment in Japan
2022-09-26
Seagen Strikes Potential $650 million Deal with LAVA Therapeutics for Cancer Treatment
2022-09-26
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!